Suven Life Sciences Share Price
Suven Life Sciences Share Price Today
As of 5 Jul 2026, Suven Life Sciences share price is ₹327.60. The stock opened at ₹305.00, compared to its previous close of ₹297.95. During today's trading session, Suven Life Sciences share price moved in the range of ₹305.00 to ₹336.00, with an average price of ₹320.50 for the day. Looking at its last 52-week, the stock has touched a low of ₹124.11 and a high of ₹336.00. On the performance front, Suven Life Sciences share price has increased by 98.77% over the last six months and is up 32.12% on a year-on-year basis.
Suven Life Sciences Returns Calculator
Suven Life Sciences Shareholder Returns
Suven Life Sciences Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Apollo Hospitals | 1,25,057.00 | 62.45 | 13.20 | 20.48% | 0.32 | 17.27% | 692.92 | 0.23% | 0.70 | 103.81 |
| Max Healthcare | 1,09,728.00 | 76.08 | 10.21 | 13.42% | 0.09 | 12.97% | 91.86 | 0.18% | 0.28 | 7.37 |
| Fortis Healthcare | 73,604.60 | 69.15 | 7.44 | 10.53% | 0.23 | 12.56% | 122.24 | 0.10% | 0.16 | 3.05 |
| Aster DM Healthcare | 40,962.60 | 95.95 | 9.69 | 8.48% | 0.31 | 10.10% | 83.23 | 0.38% | 0.46 | 5.20 |
| Narayana Hrudayalaya | 40,570.70 | 50.34 | 8.94 | 17.76% | 0.76 | 11.42% | 127.10 | 0.23% | 0.85 | 24.77 |
| Global Health | 36,176.70 | 65.28 | 9.13 | 14.05% | 0.06 | 15.26% | 149.24 | 0.04% | 0.77 | 18.46 |
| KRISHNA INST OF MED SCI L | 35,097.80 | 145.08 | 9.37 | 10.74% | 0.63 | 7.99% | 93.54 | 0.00% | 0.46 | 6.52 |
| Dr. Lal Path Labs | 27,697.10 | 54.33 | 11.04 | 20.13% | 0.07 | 25.56% | 8.90 | 1.56% | 1.01 | 30.45 |
| Syngene International | 17,755.40 | 56.03 | 3.67 | 7.76% | 0.04 | 9.67% | 116.55 | 0.28% | 0.67 | 7.58 |
| Poly Medicure | 17,614.20 | 54.92 | 5.67 | 10.37% | 0.08 | 12.71% | 301.18 | 0.20% | 0.53 | 33.15 |
Suven Life Sciences Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹6.66 | ₹11.69 | ₹13.54 | ₹11.84 |
| Other Income | ₹10.90 | ₹21.13 | ₹8.45 | ₹1.60 |
| Total Revenue | ₹17.55 | ₹32.82 | ₹21.99 | ₹13.45 |
| Total Expenses | ₹178.30 | ₹146.36 | ₹146.26 | ₹139.16 |
| Profit Before Tax | -₹160.75 | -₹106.08 | -₹118.27 | -₹122.00 |
| Tax | ₹0.00 | -₹1.00 | ₹0.00 | ₹0.00 |
| Profit After Tax | -₹160.75 | -₹105.08 | -₹118.27 | -₹122.00 |
| EPS - Basic | -₹7.37 | -₹4.82 | -₹5.42 | -₹9.05 |
| EPS - Diluted | -₹7.37 | -₹4.82 | -₹5.42 | -₹9.05 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | -₹160.75 | -₹106.08 | -₹118.27 | -₹122.00 |
| Income before WC changes | -₹164.77 | -₹128.54 | -₹126.36 | -₹123.09 |
| Change in Assets | -₹0.92 | ₹4.78 | ₹8.01 | ₹3.33 |
| Change in Liabilities | ₹10.98 | ₹2.11 | ₹3.47 | -₹7.25 |
| Change in WC | ₹10.07 | ₹6.89 | ₹11.48 | -₹3.93 |
| Cash flow from Operations | -₹154.10 | -₹115.47 | -₹115.98 | -₹127.54 |
| Cash flow from Investing | ₹154.95 | ₹94.44 | -₹247.81 | -₹22.23 |
| Cash flow from Financing | -₹0.76 | -₹1.05 | ₹395.54 | ₹145.69 |
| Total Cash Flow | ₹0.09 | -₹22.09 | ₹31.75 | -₹4.07 |
| Cash (Start of the year) | ₹14.93 | ₹37.02 | ₹5.27 | ₹9.35 |
| Cash (End of the year) | ₹15.03 | ₹14.93 | ₹37.02 | ₹5.27 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹59.71 | ₹28.23 | ₹137.32 | ₹41.44 |
| Current Assets | ₹75.47 | ₹256.67 | ₹251.59 | ₹66.59 |
| Total Assets | ₹135.18 | ₹284.90 | ₹388.91 | ₹108.03 |
| Current Liabilities | ₹23.49 | ₹13.52 | ₹11.13 | ₹8.31 |
| Net Current Asset | ₹51.99 | ₹243.16 | ₹240.46 | ₹58.28 |
| Non-Current Liabilities | ₹1.71 | ₹1.35 | ₹2.46 | ₹3.57 |
| Equity Capital | ₹109.99 | ₹270.04 | ₹375.32 | ₹96.15 |
| Total Equity & Liabilities | ₹135.18 | ₹284.90 | ₹388.91 | ₹108.03 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹6.66 | ₹11.69 | ₹13.54 | ₹11.84 |
| Other Income | ₹10.73 | ₹21.13 | ₹8.45 | ₹1.60 |
| Total Revenue | ₹17.38 | ₹32.82 | ₹21.99 | ₹13.45 |
| Total Expenses | ₹64.46 | ₹49.29 | ₹48.12 | ₹53.41 |
| Profit Before Tax | -₹47.08 | -₹9.01 | -₹20.13 | -₹36.25 |
| Tax | ₹0.00 | -₹1.00 | ₹0.00 | ₹0.00 |
| Profit After Tax | -₹47.08 | -₹8.01 | -₹20.13 | -₹36.25 |
| EPS - Basic | -₹2.16 | -₹0.37 | -₹1.13 | -₹2.69 |
| EPS - Diluted | -₹2.16 | -₹0.37 | -₹1.13 | -₹2.69 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | -₹47.08 | -₹9.01 | -₹20.13 | -₹36.25 |
| Income before WC changes | -₹51.00 | -₹31.47 | -₹28.22 | -₹37.34 |
| Change in Assets | -₹0.92 | ₹4.78 | ₹8.01 | ₹3.33 |
| Change in Liabilities | ₹3.92 | -₹0.06 | -₹1.61 | -₹2.09 |
| Change in WC | ₹3.00 | ₹4.73 | ₹6.40 | ₹1.24 |
| Cash flow from Operations | -₹47.39 | -₹20.56 | -₹22.92 | -₹36.62 |
| Cash flow from Investing | ₹44.21 | -₹0.68 | -₹348.82 | -₹107.46 |
| Cash flow from Financing | -₹0.76 | -₹1.05 | ₹395.54 | ₹145.69 |
| Total Cash Flow | -₹3.94 | -₹22.30 | ₹23.79 | ₹1.61 |
| Cash (Start of the year) | ₹4.40 | ₹26.70 | ₹2.90 | ₹1.29 |
| Cash (End of the year) | ₹0.46 | ₹4.40 | ₹26.70 | ₹2.90 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹751.18 | ₹605.34 | ₹619.18 | ₹422.13 |
| Current Assets | ₹57.71 | ₹246.14 | ₹241.26 | ₹64.22 |
| Total Assets | ₹808.89 | ₹851.48 | ₹860.44 | ₹486.35 |
| Current Liabilities | ₹7.67 | ₹4.76 | ₹4.54 | ₹6.80 |
| Net Current Asset | ₹50.04 | ₹241.38 | ₹236.73 | ₹57.42 |
| Non-Current Liabilities | ₹1.71 | ₹1.35 | ₹2.46 | ₹3.57 |
| Equity Capital | ₹799.51 | ₹845.38 | ₹853.44 | ₹475.98 |
| Total Equity & Liabilities | ₹808.89 | ₹851.48 | ₹860.44 | ₹486.35 |
About Suven Life Sciences
Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).
Suven Life Sciences Financial Highlights
- Revenue: Suven Life Sciences reported revenue of ₹21.04 crore in FY26 vs ₹17.56 crore in FY25. It showed an increase of 19.82% on a yearly basis.
- Operating Profit: Suven Life Sciences reported an operating loss of ₹276.34 crore in FY26 vs ₹160.75 crore in FY25. It showed a decrease of 71.91% on a year-on-year basis.
- Net Profit: Suven Life Sciences reported a net loss of ₹276.34 crore in FY26 vs ₹160.75 crore in FY25. It showed a decrease of 71.91% on a yearly basis.
Suven Life Sciences Quarterly Result Highlights
- Suven Life Sciences reported revenue of ₹8.30 crore in Mar 2026, compared with ₹5.58 crore in Dec 2025, representing an increase of 48.75% on a quarter-on-quarter (QoQ) basis.
- Suven Life Sciences reported an operating loss of ₹45.60 crore in Mar 2026, compared with ₹101.92 crore in Dec 2025, representing an increase of 55.26% on a quarter-on-quarter (QoQ) basis.
- Suven Life Sciences reported a loss of ₹45.60 crore in Mar 2026, compared with ₹101.92 crore in Dec 2025, reflecting an increase of 55.26% on a QoQ basis.
- The earnings per share (EPS) of Suven Life Sciences stood at ₹7.37 during Mar 2026.
Similar Stocks
FAQs on Suven Life Sciences Share Price
What is Suven Life Sciences share price today?
Suven Life Sciences share price is ₹327.60 as on 03 Jul, 2026, 15:59 IST.
How has the Suven Life Sciences share price performed in the past?
In the last 1 year, Suven Life Sciences delivered a return of 32.12%. The Suven Life Sciences share price hit a high of ₹336.00 and low of ₹124.11.
How much is the Mutual Fund shareholding in Suven Life Sciences shares?
The Mutual Fund Shareholding in Suven Life Sciences was 1.79% at the end of Mar 2026.
What is the the 52-week high and low of Suven Life Sciences shares ?
The 52-week high and low of Suven Life Sciences share is ₹336.00 and ₹124.11 as of 03 Jul, 2026.
What is the market cap of Suven Life Sciences?
The market capitalisation of Suven Life Sciences is ₹7,884.14 Crores as on 03 Jul, 2026.
What are the stock symbols of Suven Life Sciences?
The stock symbol of Suven Life Sciences is SUVEN on the NSE, 530239 on the BSE, and the ISIN is INE495B01038.
What was yesterday's closing price of Suven Life Sciences shares ?
Suven Life Sciences shares closed yesterday at ₹297.95 on NSE & ₹298.65 on BSE
How to buy Suven Life Sciences shares?
To buy Suven Life Sciences shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Suven Life Sciences shares on Holidays?
No, shares of Suven Life Sciences or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Suven Life Sciences shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Suven Life Sciences?
The PE and PB ratio of Suven Life Sciences is -28.52 and 13.33 respectively, as on 03 Jul, 2026, 15:59 IST.